[go: up one dir, main page]

MX2021000555A - Tratamiento antidiabetico cardiovascular seguro. - Google Patents

Tratamiento antidiabetico cardiovascular seguro.

Info

Publication number
MX2021000555A
MX2021000555A MX2021000555A MX2021000555A MX2021000555A MX 2021000555 A MX2021000555 A MX 2021000555A MX 2021000555 A MX2021000555 A MX 2021000555A MX 2021000555 A MX2021000555 A MX 2021000555A MX 2021000555 A MX2021000555 A MX 2021000555A
Authority
MX
Mexico
Prior art keywords
cardiosafe
antidiabetic therapy
therapy
antidiabetic
cardio
Prior art date
Application number
MX2021000555A
Other languages
English (en)
Inventor
Odd-Erik Johansen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2021000555A publication Critical patent/MX2021000555A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Credit Cards Or The Like (AREA)
  • Packages (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al tratamiento antidiabético cardiovascular seguro.
MX2021000555A 2018-07-17 2019-07-16 Tratamiento antidiabetico cardiovascular seguro. MX2021000555A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP18184034 2018-07-17
EP18187272 2018-08-03
EP18197472 2018-09-28
EP18202843 2018-10-26
EP19157007 2019-02-13
EP19157226 2019-02-14
EP19177388 2019-05-29
PCT/EP2019/069131 WO2020016232A1 (en) 2018-07-17 2019-07-16 Cardiosafe antidiabetic therapy

Publications (1)

Publication Number Publication Date
MX2021000555A true MX2021000555A (es) 2021-03-29

Family

ID=67226277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000555A MX2021000555A (es) 2018-07-17 2019-07-16 Tratamiento antidiabetico cardiovascular seguro.

Country Status (12)

Country Link
US (2) US20210299129A1 (es)
EP (1) EP3823624A1 (es)
JP (2) JP2021530510A (es)
KR (1) KR20210032468A (es)
CN (1) CN112423761A (es)
AU (1) AU2019304485C1 (es)
BR (1) BR112020024793A2 (es)
CA (1) CA3103992A1 (es)
CL (1) CL2020003414A1 (es)
MX (1) MX2021000555A (es)
PH (1) PH12021550102A1 (es)
WO (1) WO2020016232A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
KR20070099527A (ko) 2004-10-08 2007-10-09 노파르티스 아게 유기 화합물의 조합물
US7863307B2 (en) 2005-07-01 2011-01-04 Merck Sharp & Dohme Process for synthesizing a CETP inhibitor
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EA029759B1 (ru) * 2009-02-13 2018-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
EP3685839A1 (en) * 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
KR20150128726A (ko) * 2013-03-15 2015-11-18 베링거 인겔하임 인터내셔날 게엠베하 심장보호 및 신장보호 항당뇨병 치료요법에서의 리나글립틴의 사용

Also Published As

Publication number Publication date
CL2020003414A1 (es) 2021-07-23
AU2019304485B2 (en) 2024-10-31
AU2019304485C1 (en) 2025-05-01
PH12021550102A1 (en) 2021-09-27
EP3823624A1 (en) 2021-05-26
BR112020024793A2 (pt) 2021-03-02
US20210299129A1 (en) 2021-09-30
JP2024124414A (ja) 2024-09-12
JP2021530510A (ja) 2021-11-11
US20240398818A1 (en) 2024-12-05
CA3103992A1 (en) 2020-01-23
WO2020016232A1 (en) 2020-01-23
CN112423761A (zh) 2021-02-26
KR20210032468A (ko) 2021-03-24
AU2019304485A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
ZA202102549B (en) Substituted tolyl as fungicides
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CA193736S (en) Skin massager
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
GEP20227403B (en) Compounds
WO2019020602A3 (en) LUMINOPHORE AND COMPOSITION
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
IL276103A (en) Combined treatment with 70cd
CA185542S (en) Table
EP4417262A3 (en) Combination therapy
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
TN2019000211A1 (en) Antitumoral compounds
MX2020010657A (es) Derivados de oxadiazolina.
MX2018015697A (es) Composición de alimentación que comprende una proteasa ácida.
MX2017014549A (es) Farmacos precursores de oxabicicloheptanos.
SG11202005711TA (en) Novel uses
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
IL282396A (en) new uses
MX2020006758A (es) Cemento de alumina.
MX2022005034A (es) Combinacion farmaceutica y uso de la misma.
CA187846S (en) Inverter
PH12021550101A1 (en) Cardio- and renosafe antidiabetic therapy
CA187847S (en) Spa filter cover